Robert Langreth

A clinical trial used to approve Amgen Inc.’s pill Tavneos was retracted Monday from the New England Journal of Medicine, putting the drug’s continued sales at risk.

Biogen Inc. shares declined after additional data from a mid-stage study of its Alzheimer’s drug diranersen failed to show convincing evidence of benefit, as a deeper dive into the results found hints of improvement in some areas.

Johnson & Johnson reported second-quarter sales above expectations on strong growth of drugs for cancer, inflammatory diseases and treatment-resistant depression.

After more than a decade of research and years of delays, Johnson & Johnson now has a robot on the market for soft tissue surgery.

Formation Bio said it has appointed former Biogen Inc. research head Michael Ehlers as its chief scientific officer, bringing a seasoned drug and biotech veteran into the AI-focused health startup.

Johnson & Johnson announced a collaboration with Sail Biomedicines to develop CAR-T therapies for immune-mediated diseases and said it now has an exclusive option to acquire the closely held company.

Moderna Inc. said a key trial for it norovirus vaccine didn’t meet the statistical criteria for early success, a blow to the company as it works to diversify beyond respiratory immunizations.

Gilead Sciences Inc. reported sales growth that beat expectations, as its drugs for HIV prevention and treatment continued to perform well.

Moderna Inc. won US regulatory approval for a flu vaccine based on mRNA technology, a victory for the company after the shot originally faced Food and Drug Administration opposition.

US regulators approved Replimune Group Inc.’s melanoma drug for patients who tried and failed immune therapy, a big victory for the drugmaker after its first two attempts to get the drug approved were rejected by the agency.